In a recent study, researchers compared the efficacy of several epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of certain types of non-small cell lung cancer. READ MORE
A report by Boehringer Ingelheim shows that non-small cell lung cancer patients may be missing out on a vital test for epidermal growth factor receptor mutations.
Research in Review
Adding a hypoxia-activated prodrug to standard care for epidermal growth factor receptor-positive non-small cell lung cancer may help to delay treatment resistance, according to a study published in PLOS Computational Biology.